ArticleCardiovascular drugs and therapy2026
Effects of Age, BMI and Creatinine Clearance on Edoxaban Plasma Concentrations in Non-Valvular Atrial Fibrillation Patients.
Article in Cardiovascular drugs and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeNon-valvular atrial fibrillation (NVAF) is a major stroke risk factor, and edoxaban is commonly used for thromboprophylaxis. However, marked interindividual variability in plasma edoxaban exposure may raise bleeding or thromboembolism risk. This study aimed to determine plasma edoxaban concentrations and identify clinical and demographic factors associated with its variable exposure in NVAF patients.
methodsThis observational study enrolled 103 adult patients with NVAF receiving standard edoxaban therapy at Zhongda Hospital, Southeast University, from December 2024 to December 2025. Trough edoxaban concentrations were measured by validated high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). Dose-normalized concentration (C/dose) was calculated to adjust for dosage differences. Pearson correlation analysis was performed to assess the associations between C/dose and age, body mass index (BMI), and creatinine clearance (CrCl).
resultsOf 103 patients, 70 (68.0%) received edoxaban 30 mg daily and 24 (23.3%) received 60 mg daily. Among those on 30 mg, trough concentrations were significantly higher in patients with moderate renal dysfunction than in those with mild dysfunction or normal renal function; among those on 60 mg, trough concentrations were significantly higher in patients with mild dysfunction than in those with normal renal function. Pearson correlation analysis showed that lower CrCl, older age, and lower BMI were significantly associated with higher edoxaban exposure.
conclusionsAge, BMI, and renal function significantly influence edoxaban exposure in NVAF patients. Thus, for elderly patients with extreme body weight or renal dysfunction, measuring plasma edoxaban levels may help optimize efficacy and reduce the risk of bleeding.
Indexed as
Identifiers
42536264What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.